MAPT and Alzheimer disease: Considering the findings in human studies, mouse AD models have been used to further understand the consequences of PGRN loss on AD-like phenotypic aspects such as Abeta plaque load, tau phosphorylation, inflammation, or synaptic loss and the protective effects of PGRN replacement in such models.